Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study assessment is performed
Subjects must have participated in core study CAIN457F2306, and must have completed the entire treatment period
Subjects must be deemed by the investigator to benefit from continued secukinumab therapy
You may not be if
Any subject taking other concomitant biologic immunomodulating agent(s) except secukinumab
Any subject who is deemed not to be benefiting from the study treatment based upon lack of improvement or worsening of their symptoms
Pregnant or nursing (lactating) women
Women of child-bearing potential, unless they are using effective methods of contraception during the entire study or longer if required by locally approved prescribing information (e.g., 20 weeks in EU)
